2. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl. 2005; 23(1): S9–17.

3. Dzau V.J., Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006; 114(25) :2850–70. https://dx.doi.org/10.1161/CIRCULATIONAHA.106.655688.

4. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардио-ренальный континуум: Патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3): 7–15.

5. Ronco C., Haapio M., House A.A. et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19): 1527–39. https://dx.doi.org/10.1016/j.jacc.2008.07.051.

6. Cohen J.B., Schrauben S.J., Zhao L. et al. Clinical phenogroups in heart failure with preserved ejection fraction: Detailed phenotypes, prognosis and response to spironolactone. JACC Heart Fail. 2020; 8(3): 172–184. https://dx.doi.org/10.1016/j.jchf.2019.09.009.

7. Finamore P., Spruit M.A., Schols J.M.G.A. et al. Clustering of patients with end-stage chronic diseases by symptoms: A new approach to identify health needs. Aging clinical and experimental research. 2021; 33(2): 407–17. https://dx.doi.org/10.1007/s40520-020-01549-5.

8. Mullens W., Damman K., Testani J.M. et al. Evaluation of kidney function throughout the heart failure trajectory – A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(4): 584–603. https://dx.doi.org/10.1002/ejhf.1697.

9. Mullens W., Martens P., Testani J.M. et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022; 24(4): 603–19. https://dx.doi.org/10.1002/ejhf.2471.

10. United Nations General Assembly. Political declaration of the 3rd High-Level Meeting of the General Assembly on the Prevention and Control of Non-Communicable Diseases: Resolution adopted by the General Assembly. UN. General Assembly. High-Level Meeting of Heads of State and Government on the Prevention and Control of Non-Communicable Diseases. New York. 2018: 7.

11. Смирнов А.В., Шилов Е.М., Добронравов В.А. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16(1): 89–115.

12. Клинические рекомендации. Хроническая болезнь почек. Ассоциация нефрологов. Рубрикатор клинических рекомендаций Минздрава России. 2021. ID: 469. Доступ: https://cr.minzdrav.gov.ru/schema/469_2 (дата обращения – 01.04.2023).

13. Johansen K.L., Chertow G.M., Gilbertson D.T. et al. United States Renal Data System 2022 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2023; 81(3S1): A8–A11. https://dx.doi.org/10.1053/j.ajkd.2022.12.001.

14. Серов В.А., Шутов А.М. Кардиоренальные взаимоотношения при хронической сердечной недостаточности. Ульяновский государственный университет. 2011.

15. Ефремова Е.В., Шутов А.М. Прогностические биомаркеры при хроническом кардиоренальном синдроме у пациентов старшей возрастной группы. Нефрология и диализ. 2022; 24(2): 357–365.

16. Levin A., Stevens P., Bilous R.W., Coresh J. Kidney Disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3(1): 1–150. https://dx.doi.org/10.1038/kisup.2012.73.

17. Li P.K., Garcia-Garcia G., Lui S.F. et al. Kidney health for everyone everywhere – from prevention to detection and equitable access to care. Kidney Med. 2020; 2(1): 5–11. https://dx.doi.org/10.1016/j.xkme.2020.01.002.

18. Heras M., Garcia-Cosmes P., Fernandez-Reyes M., Sanchez R. Natural progression of renal function in the elderly: Analysis of poor prognosis factors associated with chronic kidney disease. Nefrologia. 2013; 33(4): 462–69. https://dx.doi.org/10.3265/Nefrologia.pre2013.Jan.11806.

19. Tangri N., Stevens L.A., Griffith J. et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011; 305(15): 1553–59. https://dx.doi.org/10.1001/jama.2011.451.

20. Ortiz A., Wanner C., Gansevoort R.; ERA Council. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: A position statement by the Council of the European Renal Association. Eur J Prev Cardiol. 2022; 29(17): 2211–15. https://dx.doi.org/10.1093/eurjpc/zwac186.

21. Fink H.A., Ishani A., Taylor B.C. et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012; 156(8): 570–81. https://dx.doi.org/10.7326/0003-4819-156-8-201204170-00004.

22. Koncicki H.M., Swilder M.A. Decision making in elderly patients with advanced kidney disease. Clin Geriatr Med. 2013; 29(3): 641–55. https://dx.doi.org/10.1016/j.cger.2013.05.004.

23. Farrington K., Covic A., Nistor I. et al. Clinical practice guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR<45 mL/min/1.73 m2): A summary document from the European Renal Best Practice Group. Nephrol Dial Transplant. 2017; 32(1): 9–16. https://dx.doi.org/10.1093/ndt/gfw411.

24. Терещенко С.Н., Галявич А.С., Ускач Т.М. с соавт. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 311–374.

25. Ефремова Е.В., Шутов А.М., Подусов А.С. Биомаркеры миокардиальной и почечной дисфункции при хронической сердечной недостаточности. Нефрология и диализ. 2020; 22(2): 181–188.

26. Schaub J.A., Coca S.G., Moledina D.G. et al. Amino-terminal Pro-B-type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: A systematic review and meta–analysis. JACC Heart failure. 2015; 3(12): 977–89. https://dx.doi.org/10.1016/j.jchf.2015.07.014.

27. Hajjar V., Schreiber M.J. Does measuring natriuretic peptides have a role in patients with chronic kidney disease? Cleve Clin J Med. 2009; 76(8): 476–78. https://dx.doi.org/10.3949/ccjm.76a.08065.

28. Park S., Cho G.Y., Kim S.G. et al. Brain natriuretic peptide levels have diagnostic and prognostic capability for cardio-renal syndrome type 4 in intensive care unit patients. Crit Care. 2009; 13(3): R70. https://dx.doi.org/10.1186/cc7878.

29. Ефремова Е.В., Шутов А.М., Макеева Е.Р. с соавт. Фактор, индуцируемый гипоксией-1 (HIF-1), как биомаркер острого повреждения почек у больных с острой декомпенсацией хронической сердечной недостаточности. Кардиология. 2019; 59(2S): 25–30.

30. Руденко Т.Е., Кутырина И.М., Васильева М.П. Натрийуретические пептиды: диагностическое и прогностическое значения при хронической болезни почек. Клиническая нефрология. 2013; (2): 5–9.

31. McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–726. https://dx.doi.org/10.1093/eurheartj/ehab368.

32. Heidenreich P.A., Bozkurt B., Aguilar D. et al. 2022 AHA/ACC/HFSA guidelines for the management of heart failure: A report of the American College of Cardiology /American Heart Association joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17): e263–e421. https://dx.doi.org/10.1016/j.jacc.2021.12.012.

33. Nagueh S., Smiseth O.A., Appleton C.P. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4): 277–314. https://dx.doi.org/10.1016/j.echo.2016.01.011.

34. Tong A., Manns B., Wang A.Y.M. et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018; 94(6): 1053–68. https://dx.doi.org/10.1016/j.kint.2018.08.018.

35. Hill L., Geller P.T., Baruah R. et al. Integration of a palliative approach into heart failure care: A European Society of Cardiology Heart Failure Association position paper. Eur J Heart Fail. 2020; 22(12): 2327–39. https://dx.doi.org/10.1002/ejhf.1994.

36. Kalantar-Zadeh K., Li P.K.T., Tantisattamo E. et al. World Kidney Day 2021: Living well with kidney disease by patient and care partner empowerment – Kidney health for everyone everywhere. Am J Kidney Dis. 2021; 77(4): 474–77. https://dx.doi.org/10.1053/j.ajkd.2021.01.001.

37. Клинические практические рекомендации KDIGO 2020 по тактике ведения диабета при хронической болезни почек. Нефрология и диализ. 2021; 23(S2): 9–121.

38. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995; 273(18): 1450–56.

39. Damman K., Gori M., Claggett B. et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart failure. 2018; 6(6): 489–98. https://dx.doi.org/10.1016/j.jchf.2018.02.004.

40. Guo Y., Ren M., Wang T. et al. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF. Front Cardiovasc Med. 2022; 9: 955780. https://dx.doi.org/10.3389/fcvm.2022.955780.

41. Fu S., Xu Z., Lin B. et al. Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis. Front Med (Lausanne). 2021; 8: 657067. https://dx.doi.org/10.3389/fmed.2021.657067.

42. Bakris G.L., Agarwal R., Anker S.D. et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020; 383(23): 2219–29. https://dx.doi.org/10.1056/NEJMoa2025845

43. Перепеч Н.Б., Трегубов А.В., Михайлова И.Е. Оценка профессиональных знаний и приверженности врачей рекомендациям по диагностике и лечению больных хронической сердечной недостаточностью. Кардиология. 2022; 62(5): 53–61.